IL6 and COVID-19: As shown in the Table 1, systematic reviews indicated that biomarkers such as cardiac troponin and N-terminal pro-B-type natriuretic peptide (NT-proBNP), as well as secondary markers, such as creatine kinase-myocardial bound (CK-MB), myoglobin, IL6, and CRP provided a prognostic tool in helping to early identify patients with the severe disease and that are susceptible to developing cardiovascular manifestations of COVID‐19 (Shafi et al., 2020; Alzahrani and Al-Rabia, 2021).